Analysis of Antithrombotic Therapy and Thromboembolic Events in Patients with Atrial Fibrillation Complicated with Coronary Heart Disease Based on CT examination
CHEN Yafeng;XU Xiaodong;JIN Luping;LI Shen;Jingmen First People's Hospital;
Objective To analyze the status quo of antithrombotic therapy and thromboembolic events in patients with atrial fibrillation complicated with coronary heart disease. Methods A total of 60 patients who underwent a diagnosis and gave treatment with atrial fibrillation combined coronary heart disease(CHD) from November 2017 to October 2018 was selected as the research object. They were randomly divided into control group and research group according to the contrast pattern. The control group 30 cases was treated with implementation of aspirin in patients with clopidogrel treatment, and the research object was treated on the basis of control group with warfarin treatment. After 1 year's treatment, the two groups of patients were followed up for observation, thromboembolism and bleeding events in patients with bleeding were recorded. Results There was 1 case(3.33%) of cerebral embolism occurred in in the study group and 5 cases(16.67%) in the control group, and the difference was not statistically significant(P0.05). There were 3 cases(10.00%) serious bleeding events occurred in the study group and 4 cases(13.33%) in the control group. There was no statistically significant difference in bleeding incidence between the study group and the control group(P0.05). Conclusion The clinical efficacy and safety of aspirin combined with clopidogrel for patients with atrial fibrillation complicated with coronary heart disease are similar to that of aspirin combined with clopidogrel combined with warfarin.
【CateGory Index】： R541.75;R541.4